TriangleTL118 Capsule (NCT06010342)
TL118 Capsule trial for Solid Tumor (NCT06010342). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with advanced or metastatic solid tumors carrying an NTRK1, NTRK2 or NTRK3 fusion, without another cancer-driving alteration. Cancer must have progressed after treatment, or standard treatment must be unsuitable. Previous TRK-inhibitor use is restricted.
The idea: take TL118 capsules at 252 milligrams twice daily in 28-day cycles. TL118 blocks TRK growth signals produced by these fusion proteins. Researchers measure tumor response and safety; at least one measurable lesion is required.
This phase 2 study plans 60 patients. Teligene US sponsors four recruiting US locations.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.